MD Labs

MD Labs is a biotechnology and healthcare company based in the United States. Since its founding in 2011, the company has focused on clinical lab excellence, specializing in prescription monitoring toxicology. Co-Founders Denis Grizelj and Matthew Rutledge aimed to create a more provider-friendly testing service that delivers prompt, accurate, reliable, and easy-to-understand results. MD Labs employs state-of-the-art technology and offers a wide array of analyte testing. The company's team of PhDs and clinical technologists constantly adds services based on client requests and pharmacotherapeutic trends, thus providing quick, accurate, and cost-effective drug testing while enhancing patients’ prescription adherence and overall patient care. In 2014, MD Labs expanded its services to include pharmacogenetic (PGX) testing to help providers better understand individual patient responses to prescription medications and reduce adverse drug reactions. Currently, there is no publicly available information regarding the company's last investment or its investors.